Apnimed Files for US IPO to Support Sleep Apnea Drug Commercialization
() -- Apnimed filed for a US initial public offering to help fund the commercialization of its oral obstructive sleep apnea drug, Bloomberg reported Friday. The late-stage drug developer said it submitted a new application to the US Food and Drug Administration in April for Oxnimbi, a fixed-dose tablet for obstructive